Exosomal microRNAs (exomiRNAs) have emerged as promising biomarkers for the early clinical diagnosis of osteoporosis. However, their limited abundance and short length in peripheral blood present significant challenges for the accurate detection of exomiRNAs. Herein, we have designed and implemented an efficacious fluorescence-based biosensor for the highly sensitive detection of exomiRNA associated with osteoporosis, leveraging the enhancing 3D DNA walker-induced CRISPR/Cas12a technology. The engineered DNA walker is capable of efficiently transforming target exomiRNA into amplifying DNA strands, thereby enhancing the sensitivity of the developed biosensor. Concurrently, the liberated DNA strands serve as activators to trigger Cas12a trans -cleavage activity, culminating in a significantly amplified fluorescent signal for the highly sensitive detection of exomiRNA-214. Under optimal conditions, the devised technology demonstrated the capacity to detect target exomiRNA-214 at concentrations as low as 20.42 fM, encompassing a wide linear range extending from 50.0 fM to 10.0 nM. Moreover, the fluorescence-based biosensor could accurately differentiate between healthy individuals and osteoporosis patients via the detection of exomiRNA-214, which was in agreement with RT-qPCR results. As such, this biosensing technology offers promise as a valuable tool for the early diagnosis of osteoporosis.
Keyphrases
- sensitive detection
- loop mediated isothermal amplification
- quantum dots
- crispr cas
- single molecule
- circulating tumor
- postmenopausal women
- bone mineral density
- genome editing
- cell free
- label free
- peripheral blood
- end stage renal disease
- nucleic acid
- energy transfer
- newly diagnosed
- high glucose
- photodynamic therapy
- body composition
- living cells
- peritoneal dialysis
- chronic kidney disease
- machine learning
- artificial intelligence
- prognostic factors
- gold nanoparticles
- deep learning
- microbial community
- big data